WishBone Medical, Inc. Names Andrew J. Miclot as President

Posted On January 4, 2018 By OrthoSpineNews In Extremities /

Warsaw, Indiana, January 4, 2018 — WishBone Medical, Inc., a new global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants in sterile packed, single-use disposable kits, announces that Andrew “Andy” J. Miclot has taken on the role of President and will continue in his role as Vice Chairman and Director on the WishBone Medical Board of Directors.

Mr. Miclot is a seasoned executive with almost 40 years of global Medical Device experience. He has been President and CEO of several Medical Device Companies with executive leadership positions, put together world-class management teams and completed and integrated acquisitions globally. He has had success in early stage and in Fortune 500 companies turning around unprofitable and growing primarily Orthopedic and ENT companies. Early experience included growing sterile packed, single-use, disposable kit Medical Device companies.

He is joining WishBone Medical after turning around Micro Machine as President and CEO, an orthopedic company with offices in Warsaw, IN and Kalamazoo MI. Recent experience includes General Manager ENT /Senior Vice President and Officer of ArthroCare where he increased annual revenue from flat to three years of double digit growth generating 33% of the revenue and 50% of the profit for the entire company.

Andrew was President/CEO and Director of Ascension Orthopedics delivering 15% increase the first year, after two consecutive years of flat sales. He was Senior Vice President of Orthofix where he propelled revenue by 15% in orthopedics that included trauma and external fixation products.

As Senior Vice President/Officer and IRO, he propelled Symmetry Medical, for over thirteen years, from a $10 million breakeven medical device company to $300 million and was key in the NYSE IPO raising $120 million, surpassing Wall Street expectations and generating $220 million via a secondary offering. Other Medical Device Supplier experience included the Executive Vice President of Micro Technologies.

He was Director of Medical Products at DePuy Orthopedics, driving revenues from $64 to $80 million. Responsibilities included trauma, sports medicine, surgical instruments and customs for spine, knee, shoulder, foot, trauma and hip Products. Prior to DePuy, he had several Marketing and Sales leadership positions at Zimmer for over five years in three Divisions; Patient Care, Hall Surgical and Trauma.

Early experience includes: Vice President of Ulti-Med, disposable products for the US and Asia, Medline, as the youngest Director, disposable textile and Custom Sterile Procedure Trays, DeRoyal, Sales Manager with orthopedic soft goods and Custom Sterile Procedure Trays and American Hospital Supply/Hospitex, Sales Manager that turned around a territory ranked worst of 50 to number three in two years and then promoted to Sales Trainer.

Nick Deeter, WishBone Medical’s Founder, Chairman and CEO commented, “We are delighted that Andy is joining WishBone Medical as Global President. He has extensive and relevant global leadership experience in Orthopedics and with single-use, sterile Medical Devices and a strong record of success. Andy will also remain as the Vice Chairman and Director of WishBone Medical’s Board of Directors and we appreciate his guidance over the last year.”

Andy currently serves on three Boards; WishBone Medical as Vice Chairman and Director, Micro Machine as Director and Precision Optics as Director (Public Company). Also, he is on two Advisory Boards; Indiana University Arts and Sciences Alumni Board and ODT (Orthopedic Design and Technology). He was one of a small group of Founders in “The Institute of Orthopaedic Enlightenment” started by Knowledge Enterprises. He has been key note speakers and panel discussion leaders at several Orthopedic and ENT conferences.

He has a BA in Speech and Hearing Sciences and an MA in Audiology from Indiana University, and an MBA from Lake Forest Graduate School of Management.

About WishBone Medical, Inc.

WishBone Medical, a Global pediatric orthopedic company, is committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.

For more information, contact Andrew Miclot, Vice Chairman and President, at 574-306-4006 or email CustomerService@WishBoneMedical.com

OrthoPediatrics Corp. Expands PediPlates® Franchise with Titanium System

Posted On January 4, 2018 By OrthoSpineNews In Extremities, Top Stories /

WARSAW, Ind., Jan. 03, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce the launch of Titanium PediPlates®, the Company’s 24^thsurgical system. The titanium implant system expands OrthoPediatrics’ already comprehensive physeal tethering offering and includes both O-Plates and I-Plates as well as solid and cannulated low-profile screws. As a market leader in guided growth, OrthoPediatrics’ PediPlates technology harnesses the power of the growth plate through a simple, minimally invasive, and reversible tethering technique.

Joe Hauser, OrthoPediatrics’ Vice President of Trauma and Deformity Correction, noted that titanium PediPlates provide another correction option to pediatric orthopedic surgeons worldwide. “Adding a titanium offering to OrthoPediatrics’ market leading PediPlates physeal tethering franchise expands physicians’ treatment options, especially in patients who have a nickel allergy. The launch of our 24^th surgical system strengthens our strategy to provide pediatric orthopedic surgeons with superior options for treating children.”

About PediPlates®
The PediPlates® system, which includes the I-Plate, O-Plate, and Delta Plate, provides a physeal tethering technique that does not disrupt the integrity of the physis, or growth plate. It features simple plate and screw constructs that span the growth center and restrain the physis by inhibiting growth where the plates and screws are applied. The system also features stainless steel plates and screws, which provide excellent strength, resistance to breakage, and ease of removal.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 24 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 35 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

WishBone Medical, Inc. Releases Broken Screw Removal and K-Wire Systems

Posted On January 2, 2018 By OrthoSpineNews In Extremities /

WARSAW, Ind., Jan. 02, 2018 (GLOBE NEWSWIRE) — WishBone Medical, Inc., a new global pediatric orthopedic company, has announced the official launch of the single-use, sterile packed Broken Screw Removal and K-Wire Systems. The Broken Screw Removal System is available in three different sizes: 2.7mm, 3.5mm and 4.5mm and is designed to remove broken, stripped and cold-welded screws.

The K-Wire Systems are available in five different configurations; Pediatric Elbow Combo Kit (1.6mm & 2.0mm K-Wires), Pediatric Long Bone Combo Kit (2.0mm & 2.5mm K-Wires), Three Pediatric Extremity Combo Kits; Small (0.7mm & 0.9mm K-Wires), Medium (0.9mm & 1.25mm K-Wires) and Large (1.25mm & 1.6mm K-Wires). Each system includes two different sizes of wires, protective pin covers and instruments.

Nick Deeter, WishBone Medical’s Founder and CEO added, “The Broken Screw Removal and K-Wire Systems both address current issues that Pediatric Surgeons face with their small patients. They need products that are sterile, easy to find, easy to use and designed for pediatric patients. We strongly believe that having these products readily available in sterile packed, single-use kits will be a game changer in the operating room.”

To learn more about WishBone Medical, visit www.WishBoneMedical.com

About WishBone Medical, Inc.

For more information, contact Andrew Miclot, Vice Chairman and President, at 574-306-4006 or email CustomerService@WishBoneMedical.com

Bone Index Ltd. Announces AMA Issues New Reimbursement Code for Bindex Osteoporosis Measurement

Posted On January 2, 2018 By OrthoSpineNews In Extremities, Top Stories /

HELSINKI, Jan. 2, 2018 /PRNewswire/ — Bone Index Ltd., one of Europe’s top new manufacturers of medical devices, announces that the American Medical Association (AMA) has issued a new Category III CPT® code* for Bindex® measurement to help physicians in diagnosing osteoporosis.

“In osteoporosis screening and diagnostics area, it has taken about 20 years since the last new code and therefore this new CPT code is a huge step for healthcare operators to provide highly needed osteoporosis examinations. This is also very strong evidence that Bindex is a new and unique medical device which provides significant improvement in osteoporosis screening and diagnostics in US,” says Bone Index’s CEO, Dr. Ossi Riekkinen.

Bindex® point-of-care device measures the cortical bone thickness of the tibia and the algorithm calculates the Density Index, a parameter which estimates bone mineral density at the hip as measured with DXA. Bindex detects osteoporosis with 90% sensitivity and specificity and will significantly help physicians with diagnosis.

Undiagnosed osteoporosis is a worldwide challenge. In the US alone osteoporosis is responsible for two million broken bones every year, costing over 19 billion dollars. Experts forecast that by 2025, the costs will rise to 25.3 billion dollars. One of the biggest challenges is the limited availability of osteoporosis diagnostics since bone density scans are mostly performed in hospitals with large DXA X-ray machines that entail high costs. “This is why Bindex® is a game-changer,” says Dr. Riekkinen.

Bindex® has a total of 19 patents globally including the US, China, Japan and large European countries. “Now Bindex is used by the US’s leading provider of direct to consumer preventive health screenings, Life Line Screening, and in addition, for example, neurosurgeries are using Bindex as a pre-operative measurement. The overall aim is to prevent osteoporotic fractures and improve the quality of life for families in the US,” Dr. Riekkinen concludes.

For more information:

Bone Index Ltd.
Dr. Ossi Riekkinen
CEO
ossi.riekkinen@boneindex.fi
+358-50-363-2797
www.bindex.fi/en/

*0508T: Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia. Effective date July 1, 2018. https://www.ama-assn.org/sites/default/files/media-browser/public/cpt/cpt-category3-codes-descriptors.pdf

About Bone Index:

Founded in 2011 and based in Kuopio, Bone Index Finland Ltd. specializes in the development of measuring devices for osteoporosis screening and diagnosis.

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/bone-index/r/bone-index-ltd–announces-american-medical-association-issues-new-reimbursement-code-for-bindex-oste,c2424125

The following files are available for download:

http://news.cision.com/bone-index/i/bindex-kuva,c2314687

Bindex kuva

SOURCE Bone Index

Paragon 28® launches the Gorilla® Lateral Column Plating System designed to address the cuboid and lateral column in cases of Charcot deformity

Posted On December 22, 2017 By OrthoSpineNews In Extremities, Top Stories /

ENGLEWOOD, Colo., Dec. 22, 2017 /PRNewswire/ — Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation that help to streamline procedures, allow surgeons flexibility in technique and approach, and facilitate reproducible results benefitting both the surgeon and patient.

The Gorilla® Lateral Column Plating System was developed to offer surgeons a dedicated plating system designed to aid in the stabilization, fusion and fixation of the lateral column. This construct allows for strength, stability and compression throughout the lateral column which can help address certain cases of Charcot reconstruction where plantar subluxation of the cuboid may result in ulceration. This plate and screw construct consists of a dorsal plate placed on the 4^th metatarsal, 5^th metatarsal and cuboid that can accept a 5.5 mm Type II Anodized, non-locking, solid plate screw. This screw interfaces with the plate and is intended to span from the space between the 4^th and 5^th metatarsals, through the cuboid and into the posterior aspect of the calcaneus.

The Gorilla® Lateral Column Plating System contains system specific instrumentation to help facilitate insertion of the 5.5 mm solid plate screw as well as a unique templating system. This templating system not only aids in determining the correct size and location of the plate, but more importantly aids in the creation of a reamed space in a specific location between the 4^th and 5^th metatarsals. A Joint Finding Paddle is included and is intended to center the template allowing for equal reaming of the 4^th and 5^th metatarsals to allow room for the 5.5 mm solid plate screw to be placed and achieve optimal screw trajectory.

This addition to the Gorilla® R3CON Plating System family leverages all the benefits of the Gorilla System including the ability for all of the standard plate holes to accept either 2.7 mm, 3.5 mm or 4.2 mm locking and non-locking plate screws as well as a robust assortment of foot and ankle specific instrumentation.

Paragon 28® is grateful for the significant contributions Dr. Douglas Blacklidge, DPM has made as the surgeon designer of this system.

CONTACT:
Jim Edson
Director of Product Management and Marketing
jedson@paragon28.com

SOURCE Paragon 28

Fuse Medical, Inc. Signs Definitive Purchase Agreement to Acquire CPM Medical Consultants, LLC

Posted On December 21, 2017 By OrthoSpineNews In Biologics, Extremities, Recon, Spine /

December 19, 2017

RICHARDSON, Texas–(BUSINESS WIRE)–Fuse Medical, Inc., (OTC: FZMD), (“Fuse” or the “Company”), announced today that it signed a definitive purchase agreement to acquire CPM Medical Consultants, LLC (“CPM”), a privately-owned nationwide distributor of medical device implants and biologics.

CPM is a stocking distributor with an extensive portfolio of orthopedic implants for total joint reconstruction, sports medicine, internal and external fixation products for extremities, and full spinal implants and instrumentation. CPM also offers an extensive assortment of biologics, which include human allograft with cell based products, regenerative tissue, and amniotic fluids to augment all types of surgical procedures.

Fuse expects the transaction to be accretive to 2018, and it anticipates the 2018 consolidated company revenues generated from its product sales and distribution to be at approximately $35 million. The transaction is subject to customary conditions of closing, which is expected to occur by December 31, 2017. Following the transaction, CPM will be a wholly-owned subsidiary of Fuse.

Management Commentary on Acquisition

Christopher C. Reeg, Chief Executive Officer of Fuse, said, “We are thrilled to have the CPM family join the Fuse team, and look forward to welcoming new business associates to Fuse. We are confident that the consolidated Fuse and CPM organizations will provide the necessary platform to achieve our numerous growth and expansion goals.”

“The acquisition of CPM is an ideal complement to our strategic objectives as it brings an experienced and proven distribution organization consisting of direct sales employees, independent sales agents, and sub-distributors who are focused in specific surgical areas. In developing our strategies in this market sector, we believe this new sales channel will provide us with an opportune pipeline for the expansion of national distribution and the launch of new product offerings, both internally developed and acquired,” added Mr. Reeg.

Mark W. Brooks, CPM Founder and Owner, stated, “We are excited with the expected benefits both organizations will gain from this transaction. CPM brings the ideal combination of broad product assortment, sales and distribution, and employee talents in a strategic market sector with outstanding growth potential. We expect our extensive product portfolio to strengthen and complement Fuse.”

“The prospect of combining the collective Fuse and CPM product portfolios is synergistic to both organizations,” commented Mr. Brooks.

About Fuse Medical, Inc.

Fuse provides a broad portfolio of orthopedic implants including internal and external fixation products; upper and lower extremity plating; total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; human allografts, substitute bone materials, and tendons; and regenerative tissues and fluids to augment orthopedic surgeries and wound care. For more information about Fuse, please visit: www.fusemedical.com.

Forward-Looking Statements

Certain statements in this press release, including those related to an anticipated purchase of all of the outstanding membership units and plans for the consolidated company, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Contacts

Fuse Medical, Inc.
Devon Peddie, 469-862-3030
Investor Relations Analyst
Facsimile 469-862-3035
info@Fusemedical.com

Wright Medical Group N.V. Announces Acquisition of IMASCAP SAS

Posted On December 18, 2017 By OrthoSpineNews In Extremities, Financial, Top Stories /

AMSTERDAM, The Netherlands, Dec. 14, 2017 (GLOBE NEWSWIRE) — Wright Medical Group N.V. (NASDAQ:WMGI) today announced the acquisition of IMASCAP SAS, a leader in the development of software-based solutions for preoperative planning of shoulder replacement surgery. The transaction ensures exclusive access to breakthrough software enabling technology and patents to further differentiate Wright’s product portfolio and to further accelerate growth opportunities in Wright’s global Extremities business.

Under the terms of the agreement with IMASCAP, Wright acquired 100% of IMASCAP’s outstanding equity on a fully diluted basis for total consideration, net of acquired cash, of €75.1 million or approximately $88.8 million, consisting of approximately €39.7 million, or approximately $46.9 million, in cash and approximately €13.2 million, or approximately $15.6 million, of Wright ordinary shares, payable at closing, and approximately €22.2 million, or approximately $26.3 million, in potential earnouts and milestone payments for new software modules and a potential future implant system.

IMASCAP’s Glenosys technology is the preoperative planning software behind Wright’s BLUEPRINT™ 3D planning software, which allows the surgeon to simulate the position of a shoulder prosthesis using CT image data. The surgeon is able to visualize the shoulder in 3D and rotate through the complete range of motion in any direction. Before the surgery, the surgeon can optimize the surgical plan adapted to the patient to choose the best implant from a range of possibilities. With its simple and intuitive interface, this virtual surgical plan is seamlessly translated into the operating room on the day of surgery offering the potential for reduced surgical time, better outcomes and less inventory.

Robert Palmisano, president and chief executive officer, commented, “Wright, and previously Tornier, has been involved with IMASCAP for many years with our BLUEPRINT case planning software, and we have seen first-hand the innovation, creativity and differentiated solutions that the IMASCAP team has developed. Software-enhanced solutions are the future, and with the acquisition of IMASCAP, we have the opportunity to take a significant lead in this area. We are thrilled that we had an opportunity to acquire IMASCAP, which is the company that has developed the technology behind our BLUEPRINT case planning software for our shoulder portfolio. This is a highly differentiated, enabling technology for the shoulder and has a number of potential applications to enhance our PROPHECY planning for ankles as well.”

Palmisano continued, “While our BLUEPRINT planning software is a significant differentiator today, IMASCAP has a rich pipeline of potential breakthrough technologies under development and patent-pending. We believe the future of orthopaedic implant surgery will include advanced elements of artificial intelligence and augmented reality. When fully developed, we believe such software enabled surgery will leapfrog the current mechanical approaches some orthopaedic companies have developed primarily for hip and knee replacement surgery.”

Palmisano further commented, “IMASCAP is led by its founder and CEO, Jean Chaoui. Jean has an impressive background, with degrees in Biomedical Engineering from Damascus University and Telecom Brittany (Masters & PhD) with a focus in Biomedical Imaging. Jean has received 11 patents and has written more than 30 scientific publications in the field of computer assisted surgery, and he has completed multiple projects in the areas of image and bio-signal processing, artificial intelligence and brain/computer interface. He is a recent recipient of the MIT Technology Review – Top 10 French Innovators under 35 and a Fellow in the Young Transatlantic Innovative Leaders Initiative, representing France. We are delighted that Jean and the entire IMASCAP team are joining Wright.”

Jean Chaoui, president and chief executive officer of IMASCAP, added, “We are delighted to have found an excellent strategic buyer in Wright, a company that shares IMASCAP’s commitment to technological leadership and who is deeply committed to the success of our technology. We believe that Wright, with its global leadership position in the extremities market and expertise in medical education and product development, is the ideal partner to realize the full potential of IMASCAP’s technology and product pipeline and will continue to provide the focus and investment to enable it to reach its full potential. Also, very importantly, this will provide our employees with enhanced opportunities for career growth and development. We look forward to an exciting future as part of Wright Medical.”

IMASCAP has no revenues; therefore, there is no impact to Wright’s previously provided full-year 2017 annual net sales guidance of $740 million to $745 million. Due to the timing of the closing, the company anticipates incurring minimal incremental expenses in 2017, and therefore is maintaining its current full-year 2017 non-GAAP adjusted EBITDA from continuing operations guidance range of $84 million to $88 million. The company currently plans to offer this important enabling technology at no cost to physicians who are implanting Wright’s shoulder products. Wright will provide additional information on the financial impact of this transaction and 2018 guidance on its fourth quarter 2017 earnings call, which is currently scheduled for February 27, 2018.

For more information on this transaction, please refer to the investor presentation that is available in the Investor Relations section of Wright’s website at www.wright.com.

Internet Posting of Information

Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com. The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.

About Wright Medical Group N.V.

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics. For more information about Wright, visit www.wright.com.

™ and ® denote trademarks and registered trademarks of Wright Medical Group N.V. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

About IMASCAP SAS

IMASCAP SAS develops software for preoperative planning of shoulder replacement surgery. IMASCAP software system is the only system in the world allowing orthopaedic surgeons complete independence for planning, with nothing more than image data provided by CT scan of the patient. The software allows the surgeon to automatically conceive a surgical guide adapted particularly to the patient anatomy, which permits the surgeon to implant the prosthesis in a position that closely matched the software plan. The system has been developed in close collaboration with internationally recognized experts in the shoulder field, providing an innovative and practical solution to the operating room. IMASCAP is focused on applying its technical expertise to serve orthopaedic surgery by furnishing patient specific solutions and participating in the development of new generations of prostheses adapting this new and innovative technology. For more information please visit www.imascap.com.

Non-GAAP Financial Measures

To supplement the company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, the company uses certain non-GAAP financial measures in this release, including . EBITDA, as adjusted, from continuing operations. The company’s non-GAAP adjusted EBITDA from continuing operations target is measured by adding back to net loss from continuing operations charges for interest, income taxes, depreciation and amortization expenses, non-cash share-based compensation expense and non-operating income and expense. Additionally, the company’s adjusted EBITDA from continuing operations target excludes possible future acquisitions; other material future business developments; and due diligence, transaction and transition costs associated with acquisitions and divestitures. Further, this adjusted EBITDA from continuing operations target excludes any expenses, earnings or losses related to the divested large joints business, legacy Wright’s divested OrthoRecon business and legacy Tornier’s divested ankle replacement and silastic toe products. The company’s management believes that the presentation of non-GAAP financial measures provides useful information to investors. These measures may assist investors in evaluating the company’s operations, period over period. Wright’s non-GAAP financial measures exclude such items as non-cash interest expense related to the company’s 2017 convertible notes, 2020 convertible notes and 2021 convertible notes, net gains and losses on mark-to-market adjustments on and settlements of derivative assets and liabilities, write-off of unamortized debt discount and deferred financing charges following the partial settlement of 2017 convertible notes and 2020 convertible notes, mark-to-market adjustments on CVRs, transaction and transition costs and tax impacts from changes in the realizability of net operating losses, all of which may be highly variable, difficult to predict and of a size that could have substantial impact on the company’s reported results of operations for a period. It is for this reason that the company cannot provide without unreasonable effort a quantitative reconciliation to the most directly comparable GAAP measures for its 2017 financial guidance regarding non-GAAP adjusted EBITDA from continuing operations. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “look forward,” “continue,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the future anticipated success and benefits of the company’s software-based solutions for preoperative planning of shoulder replacement surgery and the company’s anticipated financial results for 2017, including net sales from continuing operations and adjusted EBITDA from continuing operations. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the failure to realize the full anticipated benefits of the company’s software-based solutions for preoperative planning of shoulder replacement surgery; risks involved in the acquisition of IMASCAP and the anticipated registration of the resale of the Wright ordinary shares issued in connection therewith; failure to integrate the legacy Wright and Tornier businesses and realize net sales synergies and cost savings from the merger with Tornier or delay in realization thereof; operating costs and business disruption as a result of the merger, including adverse effects on employee retention and sales force productivity and on business relationships with third parties; integration costs; actual or contingent liabilities; failure of the company’s recent U.S. sales force additions, focus on core product portfolio and incentives to drive U.S. lower extremities and biologics sales or delay in realization thereof; adverse effects of diverting resources and attention to providing transition services to the purchaser of the large joints business; the adequacy of the company’s capital resources and need for additional financing; the timing of regulatory approvals and introduction of new products; physician acceptance, endorsement, and use of new products; failure to achieve the anticipated benefits from approval of AUGMENT^® Bone Graft; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims and product recalls; pending and threatened litigation; risks associated with the metal-on-metal master settlement agreement and the settlement agreement with the three settling insurers; risks associated with the subsequent metal-on-metal settlement agreements and ability to obtain the additional new insurance proceeds contingent thereon; risks associated with international operations and expansion; fluctuations in foreign currency exchange rates; other business effects, including the effects of industry, economic or political conditions outside of the company’s control; reliance on independent distributors and sales agencies; competitor activities; changes in tax and other legislation; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 25, 2016 filed by Wright with the SEC on February 23, 2017 and in other subsequent SEC filings by Wright, including Wright’s Quarterly Report on Form 10-Q for the quarterly period ended September 24, 2017 filed by Wright with the SEC on November 2, 2017. Investors should not place considerable reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investors & Media:

Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
julie.tracy@wright.com

Wright Medical Group N.V.

OrthoPediatrics Corp. Appoints Samuel D. Riccitelli to its Board of Directors

Posted On December 15, 2017 By OrthoSpineNews In Extremities /

WARSAW, Ind., Dec. 15, 2017 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the appointment of Samuel D. Riccitelli to its Board of Directors as an independent member, effective immediately. The appointment of Mr. Riccitelli brings the Company’s Board to 11 members. Mr. Riccitelli will be a member of the Governance Committee of the Board.

Terry Schlotterback, Chairman of the OrthoPediatrics Board of Directors, said, “Sam brings a wealth of direct experience to the OrthoPediatrics Board that includes building medical technology companies that transitioned from private to public ownership. He also has a strong understanding of the process of novel technology development. I am excited to welcome Sam to the Board of Directors and look forward to leveraging his extensive background in the healthcare industry.”

Mr. Riccitelli, age 58, has more than 30 years of experience in healthcare, including senior leadership positions at two publicly traded companies, and currently serves as Chairman of the Board of Directors of Precipio Diagnostics (NASDAQ:PRPO). From 2012 to 2017, he served as President and Chief Executive Officer, and as a Director, at Signal Genetics, Inc., a publicly traded molecular diagnostic company that was sold to miRagen Therapeutics. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc. (“Genoptix”), a publicly traded diagnostic company that was sold to Novartis in 2011. During his 10 year tenure at Genoptix, the company completed an initial public offering and grew sales to approximately $200 million in seven years.

From 1995 to 2001, Mr. Riccitelli served in a number of R&D and general management positions for Becton, Dickinson and Company, including as a Vice President and General Manager, and as a board member for BD Ventures, L.L.C., a venture capital fund of BDX. Mr. Riccitelli also served on the Board of Directors of Exagen Diagnostics, Inc., from 2011 to 2014. Mr. Riccitelli received a B.A. in Biology from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas in Mechanical & Biomedical Engineering.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 23 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, complex spine and ACL reconstruction procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 35 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

Stimwave Appoints Industry Veteran Jim Surek as Chief Commercialization Officer and Adds Konstantin Slavin, M.D. to Medical Advisory Board

Posted On December 14, 2017 By OrthoSpineNews In Extremities /

December 14, 2017

POMPANO BEACH, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, announced the appointment of Konstantin Slavin, M.D. to its medical board of advisors and the appointment of industry veteran Jim Surek to the position of chief commercialization officer. The expansion of the team is in direct response to an ever-increasing demand for its Freedom Spinal Cord Stimulation (SCS) System and StimQ Peripheral Nerve Stimulator (PNS) System for the treatment of chronic pain.

“Every day, increasing numbers of patients are seeking non-opioid solutions to managing chronic pain, and it is essential that we do everything we can to meet that demand and to serve those patients,” said Laura Tyler Perryman, co-founder and CEO of Stimwave. “The addition of Dr. Slavin and Jim Surek strengthens our executive management team to support our high growth and to meet these market needs.”

Dr. Slavin currently serves as professor of neurosurgery at the University of Illinois at Chicago and holds several leadership roles in professional societies, including serving as president of the American Society for Stereotactic and Functional Neurosurgery and as the director at large for the International Neuromodulation Society. He is a world-renowned expert in neuromodulation, most recently publishing his second edition of “Peripheral Nerve Stimulation” and “Neurostimulation: Principles and Practice.”

“This miniature, wireless stimulator minimizes the need for surgery in patients who are already suffering from pain, while allowing on-going care and full-body MRI scan capabilities providing a viable, non-opioid option for long-term pain management,” said Dr. Slavin. “I am pleased to join their prestigious board of experts in the field.”

A 25-year industry veteran, Jim Surek joins the Stimwave team as the company’s first chief commercialization officer. Surek received his Master’s in International Management from the Thunderbird School of Global Management. Beginning his career as a spinal implant sales representative at Medtronic in 1994, Surek rose through the ranks to vice president of sales and development before taking on the role of the first vice president of sales at Advanced Bionics in 2003, which ultimately sold to Boston Scientific. He went on to become the vice president of sales at Entellus Medical, Inc., which sold to Stryker earlier this month.

“I’m thrilled to return to the field of neuromodulation with Stimwave. It’s an exciting time to be a part of a great neuromodulation team and company setting the vision for the future for all pain patients across the country,” said Surek. “Stimwave’s technology brings the future forward through its miniaturization of the electronics and elimination of a bulky, potentially dangerous implantable battery. Now, physicians have a solution to treat a tremendously larger pain patient population, since more than 80 percent of patients either cannot receive treatment or refuse the surgery option to treat their pain.”

Stimwave’s devices use Wireless Pain Relief^®technology and are 95 percent smaller than any other neuromodulation device on the market and can be anchored through an injectable method. The device delivers small pulses of energy to specific nerves, triggering a reaction that enables the brain to remap pain pathways, thus providing pain relief. Stimwave launched its FDA-cleared devices for the relief of chronic back and leg pain to a limited number of patients throughout 2015. In March 2016, Stimwave was granted FDA 510(k) for the relief of peripheral nervous system (PNS) pain, becoming the only neuromodulation device manufacturer cleared by the FDA to help reduce chronic neuropathic pain at most locations throughout the body, from back and leg pain addressed by spinal cord stimulation to PNS treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.

About Stimwave

Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management. www.stimwave.com

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

Contacts

Glodow Nead Communications
Evan Nicholson, Rosemary O’Brien, Kati Stadum, and Sarah Rogers, 415-394-6500
StimwavePR@GlodowNead.com

Episurf Medical reaches milestone of 300 implants

Posted On December 13, 2017 By OrthoSpineNews In Extremities /

Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of its 300th surgery with the Episealer® implant in the coming weeks.

“Strong clinical results, a growing user group among European surgeons, our 300th implant in production, a significant increase in the interest for the Episealer® technology within the orthopaedic industry, and most importantly, a continuous flow of successful patient outcomes. All of this sums it up, Episurf Medical is continuing to establish the Episealer® technology as a treatment alternative for early knee cartilage and bone damages“ says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.30 CET on 12 December 2017.